Particles that deliver vaccines directly to mucosal surfaces could defend against many infectious diseases.
Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.
Vaccines can be delivered to the lungs via an aerosol spray, but the lungs often clear away the vaccine before it can provoke an immune response. To overcome that, MIT engineers have developed a new type of nanoparticle that protects the vaccine long enough to generate a strong immune response — not only in the lungs, but also in mucosal surfaces far from the vaccination site, such as the gastrointestinal and reproductive tracts.
Such vaccines could help protect against influenza and other respiratory viruses, or prevent sexually transmitted diseases such as HIV, herpes simplex virus and human papilloma virus, says Darrell Irvine, an MIT professor of materials science and engineering and biological engineering and the leader of the research team. He is also exploring use of the particles to deliver cancer vaccines.
“This is a good example of a project where the same technology can be applied in cancer and in infectious disease. It’s a platform technology to deliver a vaccine of interest,” says Irvine, who is a member of MIT’s Koch Institute for Integrative Cancer Research and the Ragon Institute of Massachusetts General Hospital, MIT and Harvard University.
Irvine and colleagues describe the nanoparticle vaccine in the Sept. 25 issue of Science Translational Medicine. Lead authors of the paper are recent PhD recipient Adrienne Li and former MIT postdoc James Moon.
Only a handful of mucosal vaccines have been approved for human use; the best-known example is the Sabin polio vaccine, which is given orally and absorbed in the digestive tract. There is also a flu vaccine delivered by nasal spray, and mucosal vaccines against cholera, rotavirus and typhoid fever.
To create better ways of delivering such vaccines, Irvine and his colleagues built upon a nanoparticle they developed two years ago. The protein fragments that make up the vaccine are encased in a sphere made of several layers of lipids that are chemically “stapled” to one another, making the particles more durable inside the body.
“It’s like going from a soap bubble to a rubber tire. You have something that’s chemically much more resistant to disassembly,” Irvine says.
This allows the particles to resist disintegration once they reach the lungs. With this sturdier packaging, the protein vaccine remains in the lungs long enough for immune cells lining the surface of the lungs to grab them and deliver them to T cells. Activating T cells is a critical step for the immune system to form a memory of the vaccine particles so it will be primed to respond again during an infection.
Stopping the spread of infection
In studies of mice, the researchers found that HIV or cancer antigens encapsulated in nanoparticles were taken up by immune cells much more successfully than vaccine delivered to the lungs or under the skin without being trapped in nanoparticles.
HIV does not infect mice, so to test the immune response generated by the vaccines, the researchers infected the mice with a version of the vaccinia virus that was engineered to produce the HIV protein delivered by the vaccine.
Mice vaccinated with nanoparticles were able to quickly contain the virus and prevent it from escaping the lungs. Vaccinia virus usually spreads to the ovaries soon after infection, but the researchers found that the vaccinia virus in the ovaries of mice vaccinated with nanoparticles was undetectable, while substantial viral concentrations were found in mice that received other forms of the vaccine.
Mice that received the nanoparticle vaccine lost a small amount of weight after infection but then fully recovered, whereas the viral challenge was 100 percent lethal to mice who received the non-nanoparticle vaccine.
“Giving the vaccine at the mucosal surface in the nanocapsule form allowed us to completely block that systemic infection,” Irvine says.
The Latest Bing News on:
- Engineers use 'DNA origami' to identify vaccine design ruleson June 29, 2020 at 8:07 am
By folding DNA into a virus-like structure, MIT researchers have designed HIV-like particles that provoke a strong immune response from human immune cells grown in a lab dish. Such particles might ...
- mRNA Vaccines & Therapeutics Market Industry Size, Growth, Analysis and Forecast - 2025on June 27, 2020 at 4:16 am
RNA is a versatile technology and offers many advantages mRNA lacks genomic integration and its use has resulted in transient expression of the encoded protein This favourable safety profile makes ...
- China moves two more COVID-19 vaccines to trials, another one entering phase IIIon June 26, 2020 at 4:18 pm
China this week approved both the country’s first mRNA vaccine candidate and its first recombinant protein subunit vaccine to begin clinical trials to fight COVID-19.
- COVID-19 Vaccine Distribution Builds on Pandemic Flu Planon June 26, 2020 at 2:04 pm
Developing a SARS-CoV-2 vaccine and distribution plan is an 'insurmountable task' but can be done with timely planning that builds on lessons learned during the 2009 H1N1 influenza pandemic.
- All You Wanted To Know About Coronavirus Vaccine Science...on June 24, 2020 at 5:09 am
To accomplish that, a vaccine presents the immune system with something that looks like the invader and is essentially harmless, but nonetheless tricks the body into developing an immune response that ...
- All You Wanted To Know About Coronavirus Vaccine Science But Were Afraid To Askon June 24, 2020 at 4:26 am
Some of the technology behind coronavirus vaccine development dates back to the first vaccines; other techniques are much newer. Here are eight top strategies scientists are pursuing.
- US taxpayers are funding six COVID-19 vaccines. Here's where they're aton June 23, 2020 at 11:08 am
Here's an explanation of where this money is going.How vaccines workFirst, a short explanation of how vaccines work.When your body is attacked by a virus, your immune system makes antibodies to fight ...
- US taxpayers are funding 6 COVID vaccines. Here’s how they workon June 23, 2020 at 7:26 am
That nanoparticle with the spikes on top is the first part of the vaccine. The second part of the vaccine is a substance called an adjuvant, which is made out of a molecule found in tree bark and ...
- $3 billion in taxpayer dollars funding coronavirus vaccines. Here’s how they workon June 23, 2020 at 7:22 am
A vaccine is our surest pathway out of the pandemic — the surest way to go back to normal. Here’s an explanation of where this money is going.
- Sanofi Adds COVID-19, Flu Candidates to up to $2.3B+ mRNA Vaccine Partnership with Translate Bioon June 23, 2020 at 7:19 am
Sanofi and Translate Bio have expanded their two-year-old collaboration to develop mRNA vaccines for infectious diseases, with the phama giant nearly tripling to more than $2.3 billion its potential ...
The Latest Google Headlines on:
The Latest Bing News on:
- Vaxart Oral COVID-19 Vaccine Joins Trump’s “Warp Speed,” Ramps Up Manufacturing Capacityon June 29, 2020 at 5:00 am
Vaxart’s oral COVID-19 vaccine candidate has joined the handful of experimental vaccines being studied as part of President Donald Trump's commitment to delivering 300 million vaccine doses protecting ...
- How far away is a coronavirus vaccine? Latest news on UK and US trialson June 27, 2020 at 11:13 am
Last month, the pharmaceutical giant AstraZeneca announced a $1.2 billion deal with the US government to produce 400 million doses of the unproven coronavirus vaccine first produced in Prof Hill's ...
- Vaxart Oral Virus Vaccine Chosen by U.S. for Challenge Studyon June 26, 2020 at 10:29 am
Vaxart's oral coronavirus vaccine was chosen by the U.S. government to participate in a non-human primate challenge study.
- Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speedon June 26, 2020 at 6:02 am
The study is designed to demonstrate the efficacy of Vaxart’s oral COVID-19 vaccine candidate. Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to g ...
- Vaxart: OWS To Test Oral COVID-19 Vaccine Candidate In Non-Human Primateson June 26, 2020 at 5:34 am
COVID-19 vaccine has been selected to participate in a non-human primate challenge study, organized and funded by the U.S. Government's Operation Warp Speed. The study is designed to demonstrate the ...
- Vaxart shares skyrocket on news its COVID-19 vaccine candidate to be part of 'Operation Warp Speed'on June 26, 2020 at 4:09 am
Vaxart Inc. undefined said Friday its oral COVID-19 vaccine has been selected to take part in a non-human primate challenge study funded by the ...
- U of O scientist seeking edible vaccine for COVID-19on June 26, 2020 at 1:11 am
University of Ottawa professor and plant biologist Allyson MacLean has been busy during the pandemic creating a unique vaccine for COVID-19 — one you can eat.
- Covid-19 vaccine may work better as nasal spray instead of injectionon June 25, 2020 at 12:17 am
Scientists have claimed that coronavirus vaccine may be more effective as a nasal spray or inhaler instead of an injection, just like the influenza vaccine given to children, reported Daily Mail. ...
- Coronavirus vaccine could work better as a nasal spray than an injectionon June 24, 2020 at 10:20 am
World-leading teams at Oxford University and Imperial College London are testing their vaccines by injecting thousands of patients, but a nasal spray or inhaler may prove more effective.
- Covid-19 vaccine may work better as a nasal spray instead of an injection, top scientists claimon June 23, 2020 at 8:40 am
Researchers behind Britain's most promising Covid-19 jabs believe getting the vaccine directly into the lungs might be the best way to protect against the respiratory infection.